does glp-1 cause cancer Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management GLP-1s may reduce cancer risk

Study Population : 1,961 adults without diabetes Average age: 46 years Average baseline BMI: 37.9 Average baseline weight: 231.3 pounds 74.1% female, 25.9% male 76.6% White, 11.6% Black, 7.0% Asian, 4.8% Other Intervention : Semaglutide 2.4 mg subcutaneously once weekly (n=1,306) Placebo subcutaneously once weekly (n=655) Both groups: Individual counseling sessions every 4 weeks promoting 500-calorie deficit and 150 minutes/week physical activity Duration : 68 weeks Primary Outcome - Mean Percentage Weight Loss : Semaglutide: -14.9% (95% CI: -15.3 to -14.5) Placebo: -2.4% (95% CI: -3.0 to -1.8) Difference: -12.4 percentage points (p0.001) Secondary Outcomes - Categorical Weight Loss : 5% weight loss : 86.4% semaglutide vs 31.5% placebo 10% weight loss : 69.1% semaglutide vs 12.0% placebo 15% weight loss : 50.5% semaglutide vs 4.9% placebo 20% weight loss : 32.0% semaglutide vs 1.7% placebo Trial Completion Rates : Semaglutide: 81.7% completed 68 weeks Placebo: 82.0% completed 68 weeks High completion rates suggest good tolerability and participant satisfaction Safety Data : Gastrointestinal adverse events: 74.2% semaglutide vs 47.9% placebo Serious adverse events: 9.8% semaglutide vs 6.4% placebo Discontinuation due to adverse events: 7.0% semaglutide vs 3.1% placebo STEP 2: Diabetes Population Trial Citation : Davies M, et al

This is the single most important step between reading this guide and making a decision

The value proposition of LifeMD Telehealth has a $170 billion total addressable market (TAM) in the United States

Healthy weight loss comes from sustainable lifestyle changeseating well, staying active, and being consistent

Thicker smoothies tend to be more satisfying and digest more slowly, which aligns perfectly with your medication's effects

J Hepatol (2011) 54:121423